Imatinib Induced Molecular Response in CD34+Hematopoietic Stem and Progenitor Cells of Patients with Chronic Myeloid Leukemia Following the First Week of Therapy

被引：0
|
作者：
Bruennert, Daniela [1 ]
Czibere, Akos [1 ]
Bruns, Ingmar [1 ]
Pechtel, Sabrina [1 ]
Gattermann, Norbert [1 ]
Kronenwett, Ralf [1 ]
Haas, Rainer [1 ]
Frank, Neumann [1 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1109 / 1109
页数：1
相关论文
共 50 条
  • [41] Virally mediated MafB transduction induces the monocyte commitment of human CD34+hematopoietic stem/progenitor cells
    Gemelli, C.
    Montanari, M.
    Tenedini, E.
    Marani, T. Zanocco
    Vignudelli, T.
    Siena, M.
    Zini, R.
    Salati, S.
    Tagliafico, E.
    Manfredini, R.
    Grande, A.
    Ferrari, S.
    CELL DEATH AND DIFFERENTIATION, 2006, 13 (10): : 1686 - 1696
  • [42] Concentration-dependent stimulatory and inhibiting effects of lenalidomide on CD34+hematopoietic stem and progenitor cells in vitro
    Moehle, R.
    Drost, A.
    Mazier, A.
    Kanz, L.
    Weisel, K.
    ONKOLOGIE, 2013, 36 : 233 - 234
  • [43] Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)
    Simoes, Catia
    Gonzalez, Carmen
    Burgos, Leire
    Sarvide, Sarai
    Alignani, Diego
    Lopez, Aitziber
    Quispe, Ivan
    Perez-Simon, Jose A.
    Garcia-Fortes, Maria
    Bernal Del Castillo, Teresa
    Colorado, Mercedes
    Olave, Teresa
    Alfonso Pierola, Ana
    Prosper, Felipe
    Montesinos, Pau
    Paiva, Bruno
    BLOOD, 2023, 142
  • [44] Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase
    Jiang, Qian
    Xu, Lan-Ping
    Liu, Dai-Hong
    Liu, Kai-Yan
    Jiang, Bin
    Zhang, Xiao-hui
    Wang, Yu
    Chen, Shan-Shan
    Mo, Xiao-Dong
    Zhao, Xiang-Yu
    Chen, Huan
    Chen, Yu-Hong
    Han, Wei
    Jiang, Hao
    Qin, Ya-Zhen
    Liu, Yan-Rong
    Lai, Yue-yun
    Shi, Hong-Xia
    Lv, Meng
    Huang, Xiao Jun
    BLOOD, 2011, 118 (21) : 80 - 80
  • [45] In vitro effects of imatinib on CD34+cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
    Meng, Fankai
    Zeng, Wen
    Huang, Lifang
    Qin, Shuang
    Miao, Ningning
    Sun, Hanying
    Li, Chunrui
    ONCOLOGY LETTERS, 2014, 7 (03) : 791 - 796
  • [46] The Effect of CD34+Hematopoietic Progenitor Cell Dose on the Hematopoietic Recovery and Survival in Acute Lymphoblastic Leukemia (ALL) Patients Underwent Allogeneic Stem Cell Transplantation
    Aladag, Elifcan
    Demiroglu, Haluk
    Buyukasik, Yahya
    Aksu, Salih
    Goker, Hakan
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 422 - 422
  • [47] CD34+hematopoietic progenitor cells are a reservoir for JC Virus in natalizumab-treated MS patients
    Monaco, Maria Chiara
    Ryschkewitsch, Caroline
    Jensen, Peter N.
    Johnson, Kory
    Major, Eugene O.
    JOURNAL OF NEUROVIROLOGY, 2012, 18 : 73 - 73
  • [48] Molecular response of paediatric chronic myeloid leukemia (CML) with imatinib mesylate therapy
    Dhara, Atanu
    Mukhopadhyay, S.
    Das, S.
    Mukhopadhyay, A.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 444 - 445
  • [49] Characterization of Human CD34+Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor
    Rettig, Michael P.
    Shannon, William D.
    Ritchey, Julie
    Holt, Matthew
    McFarland, Kyle
    Lopez, Sandra
    Gabriel, Jeremy
    DiPersio, John F.
    BLOOD, 2008, 112 (11) : 1192 - 1192
  • [50] Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+hematopoietic stem and progenitor cells
    Cromer, M. Kyle
    Majeti, Kiran R.
    Rettig, Garrett R.
    Murugan, Karthik
    Kurgan, Gavin L.
    Bode, Nicole M.
    Hampton, Jessica P.
    Vakulskas, Christopher A.
    Behlke, Mark A.
    Porteus, Matthew H.
    MOLECULAR THERAPY, 2023, 31 (04) : 1074 - 1087
12345